Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory [PDF]
, 2001 Dr Tessa L. Holyoake
openalex +1 more source
Randomization in phase II trials: No exemption based on sample size
British Journal of Clinical Pharmacology, EarlyView.Conducting randomized clinical trials (RCTs) is challenging. For this reason, in earlier phases of drug development and rare diseases with limited sample sizes, there is a tendency to omit control groups and to replace them with historical information for perceived feasibility arguments.
Theodor Framke +4 more
wiley +1 more source
Preleukemia: one name, many meanings. [PDF]
, 2017 Definition of preleukemia has evolved. It was first used to describe the myelodysplastic syndrome (MDS) with a propensity to progress to acute myeloid leukemia (AML). Individuals with germline mutations of either RUNX1, CEBPA, or GATA2 can also be called
Koeffler, HP, Leong, G
core
Priapism as the first presentation of chronic myeloid leukaemia in an otherwise healthy young man
Asian Journal of Internal MedicineChronic myeloid leukaemia (CML) is a myeloproliferative neoplasm of older adults which usually presents in its chronic phase with symptoms related to increased synthesis of the myeloid cell line and suppression of erythropoiesis.
A. F. Z. Mohamed +3 more
doaj +1 more source
Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? [PDF]
, 2001 Jonas Björk +13 more
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
T315I – a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia
Advances in Laboratory MedicineBCR-ABL kinase domain mutations are an important cause of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) of which T315I is the most treatment-resilient. This study aimed to observe the frequency of T315I and its impact
Kaleem Bushra +2 more
doaj +1 more source
Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens
, 1979 Sudha Gangal +3 more
openalex +1 more source
Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission [PDF]
, 2001 Anna Guarini +6 more
openalex +1 more source
Management of chronic myeloid leukaemia [PDF]
European Journal of Haematology, 1986 openaire +5 more sources